Samsung Life Public Welfare Foundation

Hyundai Motor Company

Kia Motors Corporation

Ngk Insulators, Inc.

Pusan National University

Fev Gmbh

Medipost Co., Ltd

Medinno Inc.

Won Soon Park

Yun Sil Chang

Dong Kyung Sung

So Yoon Ahn

Akira Takahashi

Yuichi Hamazaki

Tetsuo Toyoshima

Jung Min Seo

Jin Su Park

Jin Ha Lee

Ki Hyung Joo

Young Eun Kim

Young Su Kim

Jung Wook Seo

Yoon-Sun Yang

Thomas Wittka

Alexander Vovk

Joschka Schaub

Sera Lim

Jae Ho Kim

The present disclosure relates to a pharmaceutical composition comprising an exosome derived from a thrombin-treated stem cell as an effective ingredient for preventing or treating a skin wound, a pharmaceutical formulation containing the same, and a production method thereof. Being a cell-free agent, an exosome-based therapeutic agent of the present disclosure has a low risk of carcinogenesis and no problems of graft rejection as well as being little liable to occur microvascular obstruction. The agent, which is not a cell, but a material isolated from a cell, can be subjected to medication development into an off-the-shelf product which allows for the reduction of production cost. The agent has the advantage of exhibiting outstanding angiogenesis and skin wound treatment effects even at a low concentration of exosomes thanks to the thrombin treatment effect.

Composition comprising thrombin-treated stem cell-derived exosome for treating skin wound

The present invention relates to a screening method for a therapeutic agent for pulmonary damage induced by the administration of high-concentration oxygen, and more specifically, to a screening method for a candidate material for a therapeutic agent for bronchopulmonary dysplasia (BPD) induced by the administration of high-concentration oxygen. The present inventors have discovered that FPR1 is over-expressed in lung tissues exposed to high-concentration oxygen, and as a result of focusing on the correlation between the expression of FPR1 and the development of BPD, have confirmed that BPD can be suppressed by inhibiting the expression or activity of FPR1. In view of this fact, a prophylactic or therapeutic material for BPD may be discovered in a rapid and accurate manner by checking whether the expression or activity level of FPR1 is inhibited, and thus, the screening method of the present invention may be beneficially used to effectively select and develop therapeutic agents for BPD.

Screening method for therapeutic substance for preventing or treating bronchopulmonary dysplasia (BPD)

The present disclosure relates to a method of selecting stem cells having the ability to produce extracellular vesicles with high efficiency, the method including the step of measuring the activity of protease-activated receptor (PAR)-mediated signaling pathways, stem cells selected by the method, and a method of screening an inducer for the production of extracellular vesicles. According to the present disclosure, upon treatment of stem cells with thrombin, the production of extracellular vesicles in the stem cells and the levels of proteins in the extracellular vesicles are significantly increased via PAR-mediated signaling pathways, and thus stem cells having the ability to produce extracellular vesicles with high efficiency can be efficiently selected by treating stem cells with thrombin and measuring an activation level of a PAR-mediated signaling pathway, and stem cells selected by this method can be effectively used in related research and clinical fields.

Method of selecting stem cells having ability to produce extracellular vesicles with high efficiency using activation of protease-activated receptor-mediated signaling pathways

The present invention relates to a pharmaceutical composition for preventing or treating neonatal hypoxic ischemic encephalopathy (HIE), comprising thrombin-treated stem cells or exosomes derived therefrom as an active ingredient, and a method for producing the same. According to the present invention, the thrombin-treated stem cell or the exosome derived therefrom has an increased expression of growth factors, immunoregulatory factors, antioxidation factors, or regeneration factors compared to a group not treated with thrombin and also enhances a neuronal apoptosis inhibitory effect, and thus has an advantage in that the therapeutic effect thereof on neonatal hypoxic ischemic encephalopathy (HIE) is excellent.

Composition for treating neonatal HIE

A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.

Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.

Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell

The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.

Composition for treating inflammatory brain diseases which includes stem cell as active ingredient

A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, an outlet side sealing portion, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell, where a reinforced part for reinforcing the outlet cell is formed at at least one corner portion at which the walls on a cross-section vertical to an extending direction of the cell cross each other, and wherein the inlet cell is a non-reinforced cell where the reinforced part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other.

Sealed honeycomb structure

A method of desulfurizing a lean NOx trap (LNT) of an exhaust purification system provided with the LNT and a selective catalytic reduction (SCR) catalyst includes determining whether a desulfurization feasibility condition of the LNT is satisfied, determining whether a desulfurization demand condition of the LNT is satisfied, and performing desulfurization of the LNT if both of the desulfurization feasibility condition of the LNT and the desulfurization demand condition of the LNT are satisfied, wherein the desulfurization of the LNT is performed by repeating a desulfurization lean mode and a desulfurization rich mode according to whether a mode switching condition due to a desulfurization temperature is satisfied and whether a mode switching condition due to generation of H2S is satisfied.

Exhaust purification system and method of desulfurizing lean NOx trap of exhaust purification system provided with lean NOx trap and selective catalytic reduction catalyst

The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and cellular inflammation in an intraventricular hemorrhage (IVH) animal model, and thus, can be useful in treating cerebrovascular diseases including intraventricular hemorrhage, etc.

Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient

A sealed honeycomb structure may include porous walls dividedly forming inlet cells and outlet cells extending from an end surface of an inlet side to an end surface of an outlet side, inlet and outlet side sealing portion, and an inlet side sealing portion, wherein at least one outlet cell is a reinforced cell where a reinforcing partfor reinforcing the outlet cellis formed at at least one corner portionat which the walls on a cross-section vertical to an extending direction of the cell cross each other, wherein the inlet cell is a non-reinforced cell where the reinforcing part is not formed at all the corner portions at which the walls on the cross-section vertical to the extending direction of the cell cross each other, and wherein the reinforcing partsof the reinforced cellsare formed at a section of the honeycomb structure from the end surface of the outlet side in the extending direction of the cell.

The present invention relates to a method of promoting generation of exosomes from stem cell by using thrombin. The method according to the present invention has superior effects of promoting generation of stem cell-derived exosomes and thus exosomes can be more efficiently obtained thereby compared to conventionally known methods. In addition, the method can be useful for related research.

Method for promoting generation of stem cell-derived exosome by using thrombin

The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.

Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome

A catalytic converter for a vehicle includes an LNT converter into one side of which exhaust gas discharged from an engine flows and from the opposite side of which the exhaust gas. The LNT converter traps nitrogen oxide contained in the exhaust gas under a lean environment, desorbs the trapped nitrogen oxide under a rich environment, and reduces the nitrogen oxide contained in the exhaust gas or the desorbed nitrogen oxide. A connecting housing changes a direction of a path of the exhaust gas to a vertical direction, and allows a reducing agent to be injected to the exhaust gas. An SDPF converter changes a direction of a path of the exhaust gas to a direction opposite to a direction, captures particulate matters contained in the exhaust gas, and reduces nitrogen oxide contained in the exhaust gas using the injected reducing agent.

Growing community of inventors

Seongnam-si, South Korea

Won Soon Park